Angiografin (156.81+493.19 50 ml) is a Fixed-Dose Combination (FDC) Drug Brand being manufactured and marketed by German Remedies (Zydus Cadila Healthcare Ltd.). This medicine is combination of more than one active ingredient or substance within a single pharmaceutical form type. The main active ingredients or salts in this drug are Meglumine Diatrizoate, Diatrizoic Acid Dihydrate. This drug comes in the form of Injection. The general packing available for this medicine consists of 50 ml and is priced at Rs 421.9 (arround $5.9066 US Dollar)
Drug details for Angiografin (156.81+493.19 50 ml)
Usage: Why is this medication prescribed?
The main active ingredients or salts in Angiografin (156.81+493.19 50 ml) are :
Meglumine Diatrizoate-156.81 mg
Diatrizoic Acid Dihydrate-493.19 mg
Meglumine Diatrizoate Indication (Prescribed for or used as):
For more details on Meglumine Diatrizoate, its Indication, Prescription, Usage, Dosage, Precaution, Side Effects etc, please check : Meglumine Diatrizoate..
Diatrizoic Acid Dihydrate Indication (Prescribed for or used as):
For more details on Diatrizoic Acid Dihydrate, its Indication, Prescription, Usage, Dosage, Precaution, Side Effects etc, please check : Diatrizoic Acid Dihydrate..
Angiografin (156.81+493.19 50 ml) Drug Brands Substitutes with similar Fixed-Dose Combination (FDC) :
There are 1 Fixed-Dose Combination (FDC) Drug Brands listed here as Substitutes for Angiografin (156.81+493.19 50 ml), which have same Fixed-Dose Combination of active substances or ingredients (i.e. Meglumine Diatrizoate-156.81 mg Diatrizoic Acid Dihydrate-493.19 mg). Please note that one can request a doctor or pharmacist to substitute a FDC Brand Version of the prescribed FDC drug brand, if any. Fixed-Dose Combination Drugs are being increasingly used due to the benefit of the combined effects of active ingredients given together. However, it is necessary to investigate the possible benefits in the clinical situation against possible disadvantages for each fixed combination drug and for each dose of the fixed combination drug. Potential advantages of fixed combination drugs may also include the counteracting by one ingredient of an adverse reaction produced by another one, and simplification of therapy, leading to improved compliance.